Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The actual benefit of ABILIFY in the treatment of schizophrenia remains substantial. |
Clinical Added Value
| moderate |
ABILIFY, like all other antipsychotics (including typical antipsychotics), provides a moderate improvement in actual benefit (IAB III) to the management of schizophrenia. |
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
2Wg5Nk7sqmVXDj9w
